Literature DB >> 24814406

Calcium channel blockers and prostate cancer.

Kevin R Loughlin1.   

Abstract

The relationship between calcium channel blockers and prostate cancer has been an area of increased interest to investigators. Calcium channel blockers have been shown to influence cell proliferation, differentiation, and apoptosis. Clinically, the association between calcium channel blockers and the development of prostate cancer has been controversial. However, on a basic science level, there is evidence that calcium channel blockers induce cytotoxicity in androgen receptor positive cell lines and may offer an innovative strategy for the treatment of castration-resistant prostate cancer.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Calcium channel blockers; Prostate cancer

Mesh：

Substances：

Year:  2014        PMID： 24814406     DOI： 10.1016/j.urolonc.2013.08.001

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   3.498


  9 in total

1.  Medium throughput biochemical compound screening identifies novel agents for pharmacotherapy of neurofibromatosis type 1.

Authors:  Galina Semenova; Dina S Stepanova; Sergey M Deyev; Jonathan Chernoff
Journal:  Biochimie       Date:  2017-01-06       Impact factor: 4.079

2.  High expression of N-type calcium channel indicates a favorable prognosis in gliomas.

Authors:  Guibin Li; Bhaskar Roy; Xiaoqiang Huang; Yafei Mu; Jiecheng Yuan; Yang Xia; Yue Song; Ziyue Peng
Journal:  Medicine (Baltimore)       Date:  2022-07-01       Impact factor: 1.817

3.  Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients.

Authors:  Chih-Yang Wang; Ming-Derg Lai; Nam Nhut Phan; Zhengda Sun; Yen-Chang Lin
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

4.  Oleuropein-Enriched Olive Leaf Extract Affects Calcium Dynamics and Impairs Viability of Malignant Mesothelioma Cells.

Authors:  Carla Marchetti; Marco Clericuzio; Barbara Borghesi; Laura Cornara; Stefania Ribulla; Fabio Gosetti; Emilio Marengo; Bruno Burlando
Journal:  Evid Based Complement Alternat Med       Date:  2015-11-26       Impact factor: 2.629

5.  CACNA1B (Cav2.2) Overexpression and Its Association with Clinicopathologic Characteristics and Unfavorable Prognosis in Non-Small Cell Lung Cancer.

Authors:  Xiaoyu Zhou; Wei Wang; Shu Zhang; Xudong Wang; Zhiyuan Tang; Jun Gu; Jun Li; Jianan Huang
Journal:  Dis Markers       Date:  2017-01-03       Impact factor: 3.434

6.  Voltage-gated calcium channels: Novel targets for cancer therapy.

Authors:  Nam Nhut Phan; Chih-Yang Wang; Chien-Fu Chen; Zhengda Sun; Ming-Derg Lai; Yen-Chang Lin
Journal:  Oncol Lett       Date:  2017-06-22       Impact factor: 2.967

Review 7.  Antihypertensive drugs use and the risk of prostate cancer: a meta-analysis of 21 observational studies.

Authors:  Liang Cao; Sha Zhang; Cheng-Ming Jia; Wei He; Lei-Tao Wu; Ying-Qi Li; Wen Wang; Zhe Li; Jing Ma
Journal:  BMC Urol       Date:  2018-03-07       Impact factor: 2.264

8.  Enhanced Orai1 and STIM1 expression as well as store operated Ca2+ entry in therapy resistant ovary carcinoma cells.

Authors:  Sebastian Schmidt; Guoxing Liu; Guilai Liu; Wenting Yang; Sabina Honisch; Stavros Pantelakos; Christos Stournaras; Arnd Hönig; Florian Lang
Journal:  Oncotarget       Date:  2014-07-15

9.  Validation of Novel Biomarkers for Prostate Cancer Progression by the Combination of Bioinformatics, Clinical and Functional Studies.

Authors:  Saeid Alinezhad; Riina-Minna Väänänen; Jesse Mattsson; Yifeng Li; Terhi Tallgrén; Natalia Tong Ochoa; Anders Bjartell; Malin Åkerfelt; Pekka Taimen; Peter J Boström; Kim Pettersson; Matthias Nees
Journal:  PLoS One       Date:  2016-05-19       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.